Fig. 1Mean change from the baseline to 2 weeks in fructosamine.
Fig. 2Mean change from the baseline to 2 weeks in (A) fasting plasma glucose (FPG), (B) 2-hour plasma glucose.
Fig. 3Mean change from the baseline to 2 weeks in (A) homeostasis model assessment of insulin resistance (HOMA-IR) and (B) homeostasis model assessment of β-cell function (HOMA-β).
Table 1Baseline characteristics of the subjects
Variable |
Subjects (n=25) |
Male sex |
7 (28) |
Height, cm |
159.17±8.15 |
Weight, kg |
66.57±10.35 |
SBP, mm Hg |
126.84±10.57 |
DBP, mm Hg |
77.92±9.80 |
Heart rate, beats/min |
71.24±10.82 |
Previous history |
24 (96) |
Cardiovascular |
17 (27.42) |
Gastroenteric/hepatobiliary |
6 (9.68) |
Endocrinologic/metabolic |
36 (58.06) |
Dermatologic |
1 (1.61) |
Others |
2 (3.23) |
Fructosamine, µmol/L |
244.00±19.57 |
FPG, mg/dL |
102.56±10.72 |
2-Hour plasma glucose, mg/dL |
154.92±54.53 |
Table 2Change of fructosamine, fasting plasma glucose, 2-hour plasma glucose, fasting C-peptide, and fasting insulin level at baseline and 2 weeks
Variable |
Baseline |
2 Weeks |
Difference |
P value |
Fructosamine, µmol/L |
244.00±19.57 |
241.68±23.39 |
−2.32±12.58 |
0.366 |
FPG, mg/dL |
102.56±10.72 |
101.32±9.20 |
−1.24±10.84 |
0.573 |
2-Hour plasma glucose, mg/dL |
154.92±54.53 |
141.92±42.22 |
−13.00±37.56 |
0.096 |
C-peptide (fasting), ng/dL |
2.92±1.61 |
2.73±1.31 |
−0.19±0.89 |
0.297 |
Insulin (fasting), µU/mL |
7.56±4.29 |
7.20±5.12 |
−0.36±4.30 |
0.675 |
HOMA-IR, mg/dL×µU/mL |
1.92±1.07 |
1.82±1.39 |
−0.09±1.30 |
0.725 |
HOMA-β, mg/dL×µU/mL |
72.14±44.63 |
69.09±48.49 |
−3.05±23.34 |
0.520 |